AI-081 is a differentiated bispecific antibody with robust cooperative interactions between PD1 and VEGFDosing of first patient in BIPAVE-001 ...

Citadel ended September with 91% fewer Palantir shares, despite the stock's eye-popping gains, after selling about 5.2 ...

Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. Check out my recommendation for TIL stock.

Akeso, Inc. (9926. HK) ('Akeso' or the 'Company') is pleased to announce that two of its independently developed, globally ...

Researchers report detailed structural and atomic information for glassy and liquid magnesium silicates, which are important ...

Space-grown crystals could lead to targeted cancer drugsResearchers used space-grown protein crystals to determine the ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies ...

Bright Biologics LLC reported the discovery and preclinical evaluation of BB-203, an anti-PD-L1/anti-VEGF bispecific antibody (Ab) being developed for the treatment of cancer.

The "Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 10+ ...

Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.